C-WC8RVasa Therapeutics
MMP inhibition, apelin analogs, cardiovascular aging
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-WC8R
C-WC8RC-WC8RMMP inhibition, apelin analogs, cardiovascular aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Vasa Therapeutics Closes $6M Seed Financing --> VC DATABASE MOBILE APP VENTURE SEARCH ARCHIVE ABOUT US Your Source for Venture Capital and Private Equity Financings Massinvestor/VC News Daily --> Vasa Therapeutics Closes $6M Seed Financing Back to Home 2024-01-03 Tweet ENCINITAS, CA, Vasa Therapeutics announced the closing of a $6M series seed funding led by Orphinic Scientific SA. >> Click here for more funding data on Vasa Therapeutics >> To export Vasa Therapeutics funding data to PDF and Excel, click here Vasa Therapeutics announces the closing of a $6M series seed funding led by Orphinic
Vasa Therapeutics Announces Oral Presentation on VS-214 at the 2026 Vascular Discovery Meeting of American Heart Association Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia G … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Vasa Therapeutics Raises $6 Million In Seed Funding To Develop Therapies For Cardiovascular Aging Diseases VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Vasa Therapeutics Raises $6 Million In Seed Funding To Develop Therapies For Cardiovascular Aging Diseases By Dan Anderson • Jan 4, 2024 Vasa Therapeutics Raises $6 Million In Seed Funding To Develop Therapies For Cardiovascular Aging Diseases Vasa Therapeutics – a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging – recently announced the closing of
Vasa Therapeutics Announces Closing of Seed Financing led by Orphinic Scientific SA - Orphinic Scientific About People Pipeline Shareholders Career Newsroom Get in touch Vasa Therapeutics Announces Closing of Seed Financing led by Orphinic Scientific SA "We are excited to have led the seed financing for Vasa. The company's novel biomarker strategy can lead to a personalized medicine-based therapy for HFpEF, a highly heterogenous disease, for which the currently available drugs do not provide durable improvement," said Adam Kruszewski, CEO of Orphinic. "We are also pleased to see multiple oppor
Vasa Therapeutics Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech st … ed? Vasa Therapeutics has raised a total of $8.3M across 2 funding rounds: 2024 Grant $2.3M Angel/Seed $6M Grant (2024): $2.3M, investors not publicly disclosed Angel/Seed (2024): $6M led by SeedFolio and Orphinic Scientific Key Investors in Vasa Therapeutics SeedFolio SeedFolio is a San Diego-based venture capital firm that focuses on early investments in innovative teams working on technologies aimed at combating disease and environmental challenges. The firm seeks to ident … the funding rounds? Vasa Therapeutics has recently completed 2 funding rounds: Grant on Jan 3, 2024, Angel/Seed on Jan 3, 2024. What is the total amount of funding Vasa Therapeutics has raised to date? Vasa Therapeutics has raised a total of $8.3M in funding to date. How many funding rounds has Vasa Therapeutics completed? Vasa Therapeutics has completed 2 funding rounds. How much funding did Vasa Therapeutics raise in its most recent funding round? Vasa Therapeutics raised
Vasa Therapeutics Granted FDA Fast Track Designation for VS-041, a Novel Investigational Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only New … fficacy. On October 10, 2025, the FDA cleared an Investigational New Drug application for a Phase 1c (Proof-of-Mechanism) study to assess the safety and tolerability of VS-041 in HFpEF participants ( NCT07219511 ). The Phase 1c study is the first clinical trial focused on a subpopulation of the high-risk HFpEF patients identified by an elevated level of serum endotrophin, a biomarker of poor clinical outcomes. The Fast Track designation allows Vasa the opportunity for m … a the opportunity for more frequent communication with the FDA, eligibility for rolling submission of its future New Drug Application (NDA and the potential for priority review once relevant criteria are met. "The Fast Track Designation for VS-041 treatment of HFpEF marks a significant milestone in our mission to advance a pipeline of drug candidates to address unmet medical needs in large groups of patients, capping off a year of strong execution," added Artur Plonows … nbsp; Development of VS- 041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/10-01). About Heart Failure with Preserved Ejection Fraction (HFpEF) HFpEF is a complex and progressive form of heart failure characterized by stiffening and fibroinflammation of the heart muscle and impaired relaxation despite normal contractile function. HFpEF affects ~3 million individuals in the US and ~10 … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
FDA grants Fast Track designation to VS-041 for heart failure | Vasa Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … with efficacy. On October 10, 2025, the FDA cleared an Investigational New Drug application for a Phase 1c (Proof-of-Mechanism) study to assess the safety and tolerability of VS-041 in HFpEF participants (NCT07219511). Fast Track designation is intended to facilitate the development and expedite the review of new therapies that address serious conditions with unmet medical need. The designation provides Vasa with increased access to the FDA through more frequent communication … creased access to the FDA through more frequent communications, eligibility for rolling review of future New Drug Application (NDA) components, and the potential for accelerated timelines based on alignment with the agency. …more 44 4 Comments Like Comment Share Copy LinkedIn Facebook X Chinmaya Kumar Senapati 7mo Report this comment Congratulations to the Vasa Therapeutics team. This is a meaningful milestone for HFpEF, where therapeutic innovation is urgently needed. Excite … cial reinforcement. ✅ Operational: The company has submitted the Clinical Trial Application (CTA) to the EMA for the pivotal Phase III trial of BupiZenge. 💰 Financial: This submission immediately triggered the third tranche of the investment agreement with strategic partner Sichuan Yangtian Bio-Pharmaceutical, securing a directed share issue of approximately 9.1 MSEK. With the CTA submitted and funding secured, CEO Stian Kildal and the team now aim to dose the first patient
Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photo … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Other news to note for April 15, 2026 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib m
Corsera Health combines RNAi, AI tech to create 'a world without cardiovascular disease' | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
Scientist.com Innovation Hub | Trends & Innovations Across the Pipeline --> --> --> --> Skip to Main Content Clients Our Platform Manage life science work from request to results Vendor Network Guided Buying Workflow Automation Regulatory Compliance Actionable Insights Your Pipeline Unified platform designed to support the full lifecycle of drug development Discovery & Preclinical Clinical PharmDev & Manufacturing Medical & Commercial AI Capabilities The only AI orchestration engine built for life sciences Source, Manage, and Scale External Research Request a Demo Request a Dem … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. Blog Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery Read blog … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. © 2026 Scientist Cookies Policy Global Privacy Policy We use cookies for various purposes including
Companies – ELMA Ventures LLC Approach Who we are Our Way Companies Connect Meet Ela Contact Us Perspectives Companies Airly http://airly.eu Airly offers both distributed network of air quality sensors throughout the world as well as real-time and reliable air quality data. Airly’s goals are to make invisible threats visible and to raise awareness of citizens and governments by providing them with the worldwide network of air quality sensors that monitor those threats. Authologic https://authologic.com Authologic is a system that allows businesses to verify the identity of their clients&
Eli Lilly And Company: Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform | 6ix News Home News Eli Lilly And Company Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform Business Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("L
Vasa Therapeutics' Novel Heart Failure Treatment VS-041 Reaches Key Clinical Advancement with First Dosing in Human Trials 28 June, 2026 | Sunday Home Editorial 2026 Media Pack BioPharma Exclusive Subscribe Events Login BioPharma USFDA Drug Development Pharma Research Regulatory Clinical Trial Pharma Manufacturing Product Development and Pipeline Genomic and Personalized Medicine LifeSciences Biotech Biologics Clinical & Diagnostic Rare Diseases Therapeutics Lab Lab Products Lab Testing Contract Pharma Contract Research Contract Manufacturing Healthcare Digital Health Bio Innovation P … S Research Workflows 03 June, 2026 Editor Picks Acurex Biosciences Awarded ASAP Grant to Advance Novel Parkinson’s Disease Therapeutic Research 28 May, 2026 H. Lundbeck A/S Secures South Korea Approval for Eptinezumab to Prevent Migraine in Adults 27 May, 2026 Cornerstone Robotics Wins EU CE Mark for Sentire® Surgical System, Expanding Into European Markets 27 May, 2026 AGC Biologics Selected by Teikoku Seiyaku Co., Ltd. to Advance Microbial Manufacturing for KTP-001 in Lumba
Vasa Therapeutics Secures $11M Seed Round to Revolutionize Cardiovascular Aging Therapeutics | Signalbase Signalbase Signals Pricing API docs Login Get API access Login Get API access Toggle menu Funding news · Published September 3, 2024 Vasa Therapeutics Secures $11M Seed Round to Revolutionize Cardiovascular Aging Therapeutics Recently funded · $11.0M Seed Biotechnology Get the full Vasa Therapeutics company profile Access contacts, investors, buying signals & more Open in Dashboard Vasa Therapeutics, a pioneering biotechnology company based in San Diego, has successfully raised $11 mil
Biotech Company Vasa Therapeutics Secures $6 Million in Seed Funding Round Pillsbury Connect Careers Contact 日本語 (JP) Lawyers About Us Careers Offices Bios Capabilities Our Approach Services Insights Events Blogs Press Thought Leadership Connect Careers Contact 日本語 (JP) Menu Search Close Search Search PillsburyLaw.com Search PillsburyLaw.com All Lawyers Capabilities Insights Press Release Biotech Company Vasa Therapeutics Secures $6 Million in Seed Funding Round Press Contacts: Erik Cummins , Matt Hyams , Taina Rosa , Olivia Meyer PDF Share Email Twitter LinkedIn Facebook Press Release Press C … he $6 million biotech investment, $2.3 million was supplemented by non-dilutive grant funding, according to a company press release. Click here to learn more. The Pillsbury deal team included Corporate partner Stan Lewandowski and associate Ann Kim. Tags Stan Lewandowski, Ann M. Kim, Corporate, Emerging Companies & Venture Capital, Technology, Life Sciences, Silicon Valley Home > Insights > Biotech Company Vasa Therapeutics Secures $6 Million in Seed Funding Round v
%PDF-1.4 %���� 1 0 obj > endobj 4 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > /Font 116 0 R >> endobj 30 0 obj > endobj 31 0 obj > stream x��}Ɏ$9v�>�����8�@
Vasa Therapeutics’ Lead Drug Candidate Enters Clinical Trials | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe
Medical Research - FSHD Skip to content Donate Join Cure FSHD What is FSHD? How do people get FSHD? Who can be affected by FSHD? Signs & Symptoms of FSHD Diagnosis & Genetic Testing Understanding the Genetics – Types of FSHD Early-onset FSHD (Infantile FSHD) How are people affected by FSHD? Support available for Australians living with FSHD Managing Your Health How We Help Medical Research Grant Applications Publications Glossary Clinical Trials Patient & Medical Advocacy Biotech Facio BioTherapies How You Can Help 2026 Tax Appeal Donations Volunteer With Us Corporate Partnership … Australians living with FSHD Managing Your Health How We Help Medical Research Grant Applications Publications Glossary Clinical Trials Patient & Medical Advocacy Biotech Facio BioTherapies How You Can Help 2026 Tax Appeal Donations Volunteer With Us Corporate Partnership Community Fundraising Signature Events Sydney Chocolate Ball LUXE Lunch Club Wyndham Surf Challenge Muscles For Muscles World FSHD Day Photo Gallery Video Gallery Host A Corporate Event About Us Contact … ew opportunities for treatments, and give life back to muscles. The research we fund spans from fundamental lab research to understand the mechanisms of this disease, right through to translational research to turn exciting discoveries into the treatments of the future. FSHD Global has been funding groundbreaking research into FSHD since 2007. To date, the Foundation has successfully funded 64 research grants across 11 countries, thanks to your support. How we fund research O … . How we fund research Our focus is on transparency and impact. That’s why each grant application we receive is scrutinised by our Scientific Advisory Board, and why we stipulate our scientists report their results back to us and publish their work for all to see. This keeps us accountable to our donors, supporters, and patients – because without your trust, none of our work is possible. In addition, our work is helping increase the involvement of the biotech and pharmaceutic … Technology Muscle Regeneration - Muscle Wellness Active Grants Completed Grants Grant 54 Establishing a fully characterized cell bank for FSHD Grant 71 CTRN – Clenbuterol to Target DUX4 in FSHD (Target FSHD): A Phase 1 Open label Safety and Tolerability Study of 3 Doses of Clenbuterol Grant 74 CNH Investigating Bioavailability, Distribution
All Biotechnology News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Ove … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 42 --> 42 43 --> 43 44 --> 44 45 --> 45 46 --> 46 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 A … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Lilly Launches TuneLab Platform To Give Biotechnology Companies Access To AI-Enabled Drug Discovery Models Built Through Over $1B In Research Investment Get more Drug Discovery insight with our FREE newsletter sign me up Log In or Subscribe Topics Bioinformatics Regulatory Target Research Innovation Preclinical Entrepreneurship Partners & Suppliers Research Partners Cellular Models Target Discovery Assay & Screening Imaging & Translational Models Analytical Characterization Watch Now Drug Discovery Online Live News | September 9, 2025 Lilly Launches TuneLab Platform To Give Biotech
Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging January 3, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Vasa Therapeutics, Inc. announced today the closing of series seed funding led by Orphinic Scientific SA (“Orphinic”), an … l. $6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Vasa Therapeutics, Inc. ("Vasa"), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the closing of series seed funding led by Orphinic Scientific SA ("Orphinic"), an early-stage investor focused on companies with game-changing potential. The round also included participat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Biotech Beach articles and careers information on BioSpace Skip to main content Skip to main menu Skip to user menu Jobseeker Sign in News Drug Development FDA Drug Delivery Deals Business Policy Cell and Gene Therapy Weight Loss Rare Disease Cancer Job Trends Artificial Intelligence NextGen: Top Start Ups To Watch Podcasts Reports Webinars Press Releases All News & Releases Insights Jobs Search Jobs Job Alerts Jobseeker Sign In Career Advice Companies Hotbeds More Best Places to Work Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release Subscribe Subscribe Search Jobs … r vice president, corporate strategy. Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024 1/2/2024 Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager. Longboard Pharmaceuticals Announces Positive Topline Data from the PACIF … icy More Employer Login Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release RSS Feeds Facebook This will open in a new window Twitter This will open in a new window LinkedIn This will open in a new window Instagram This will open in a new window © 1985 - 2026 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software
London Busmen Study | Vasa Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie P
Eli Wang - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Eli Wang Vice President Of Finance And Operations at Vasa Therapeutics Eli Wang 's Executive Work History Current Vice President Of Finance And Operations , Vice President Of Finance And Operations Equilar on 09/08/2025 Vasa Therapeutics Past To view Eli Wang's complete executive work history, sign up now Eli Wang 's Biography
Vasa Therapeutics Announces Upcoming Presentations at AHA Scientific Sessions 2022 | Newswise ☰ News Latest News Currently Embargoed Research News Releases Research Alert News With Video/Audio RSS Browse More Sections Medicine Science Life Business Expert Pitches Channels Medicine Science Life Business Journal News Trends and Top Stories By Location Meeting, Grants & Events Biotech Cancer COVID Clinical Trials Diabetes Genetics Infectious Disease Neuro Obesity Women's Health View all Medicine Channels Chemistry Climate Science Dinosaurs DOE Science News Engineering Materials Science … News Gulf of Mexico India/Pakistan News Iraq News View all by Location Channels Grant Funded News Medical Meetings Newswise Live - Event in Progress Newswise Live - Expert Spotlight Newswise Live - Events Scientific Meetings View all Meeting, Grants & Events Channels Sign up for the wires and see archived wires Sign Up Now Experts Expert Pitch Browse experts available to comment on breaking news Expert Query Request an expert contact, get responses directly to your inbox … development operations in Wroclaw, Poland, and successfully secured $2.3M of EU grant funding, distributed through the Polish government. In addition to the non-dilutive grant, the company has raised additional capital through a convertible note equity offering to advance its novel pipeline of three preclinical phase assets. The company's lead product candidate, VS-041, is a selective, first in class MMP inhibitor for treatment of HFpEF and other cardiovascular indicati … istan News Iraq News View all by Location Channels Meetings, Grants, and Events Grant Funded News Medical Meetings Newswise Live - Event in Progress Newswise Live - Expert Spotlight Newswise Live - Events Scientific Meetings View all Meeting, Grants & Events Channels RSS Experts Expert Pitch Expert Query Expert Directory Journalists Pricing About Member Services Accessibility Statement Newswise Live Invoice Lookup Services for Journalists Archived Wires Participating Inst
Orphinic Scientific SA - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Orphinic Scientific SA Holding Company | 2019 | Poland | www.orphinic.com Holding Company | 2019 | Poland | www.orphinic.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Orphinic Scientific SA Login to view more data 0 Patents (Medical) associated with Orphinic Scientific SA Login to view more data 5 News (Me … financing was led by Orphinic Scientific SA with participation from i&i Biotech Fund I SCSp. Proceeds will support the clinical development of VS-041 and advancement of Vasa's preclinical programs. About HFpEF and endotrophin Heart failure is a serious condition that affects more than 64 million people worldwide.1 Approximately 6.7 million Americans have heart failure, which is expected to increase to over 8.5 million Americans by 2030.2 Nearly half of patients with heart fai … inical development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01). About Vasa Therapeutics Vasa is a privately held biopharmaceutical company developing therapeutics that target pathophysiologies of cardiovascular and metabolic aging. In addition to VS-041, Vasa developed a cutting-edge platform for long-acting apelin for combination treatment with incretins in obesity … lar Aging $6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif., Jan. 3, 2024 /PRNewswire/ -- Vasa Therapeutics, Inc. ("Vasa"), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the closing of series seed funding led by Orphinic Scientific SA ("Orphinic"), an early-stage investor focused on companies with game-changing potential. The round also included participati … s stroke-focused medical device company scooped up $35 million in a Series B to fund clinical trials for MIVI’s products. Specializing in products to improve patient outcomes for neurointerventional procedures, the company’s lead devices are DAISe Thrombectomy System and Q Aspiration System. The DAISe system is designed to improve clot retrieval
Vasa Pharmachem Pvt. Ltd - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 14 Aug 2025 Vasa Pharmachem Pvt. Ltd Private Company | 1988 | India | 100-250 | www.vasapharmachem.com Private Company | 1988 | India | 100-250 | www.vasapharmachem.com Last update 14 Aug 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Vasa Pharmachem Pvt. Ltd Login to view more data 0 Patents (Medical) associated with Vasa Pharmachem Pvt. … ofile. Development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01). About Vasa Therapeutics Vasa is a privately held biopharmaceutical company developing therapeutics that target pathophysiologies of cardiovascular and metabolic aging. In addition to VS-041, Vasa developed a cutting-edge platform for long-acting apelin for combination treatment with incretins in obesity … financing was led by Orphinic Scientific SA with participation from i&i Biotech Fund I SCSp. Proceeds will support the clinical development of VS-041 and advancement of Vasa's preclinical programs. About HFpEF and endotrophin Heart failure is a serious condition that affects more than 64 million people worldwide.1 Approximately 6.7 million Americans have heart failure, which is expected to increase to over 8.5 million Americans by 2030.2 Nearly half of patients with heart fai … inical development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01). About Vasa Therapeutics Vasa is a privately held biopharmaceutical company developing therapeutics that target pathophysiologies of cardiovascular and metabolic aging. In addition to VS-041, Vasa developed a cutting-edge platform for long-acting apelin for combination treatment with incretins in obesity … lar Aging $6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif., Jan. 3, 2024 /PRNewswire/ -- Vasa Therapeutics, Inc. ("Vasa"), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the closing of series seed funding led by Orphinic Scient
Vasa Therapeutics Announces Successful Completion of First-in-Human Study for Investigational Therapy VS-041, a Small Molecule Drug Candidate for Heart Failure with Preserved Ejection Fracture Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases … ofile. Development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01). About Vasa Therapeutics Vasa is a privately held biopharmaceutical company developing therapeutics that target pathophysiologies of cardiovascular and metabolic aging. In addition to VS-041, Vasa developed a cutting-edge platform for long-acting apelin for combination treatment with incretins in obesity … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
I am very honored to be a member of the award-winning Vasa Team! | Artur Plonowski | 10 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … st Artur Plonowski 8mo Report this post I am very honored to be a member of the award-winning Vasa Team! Vasa Therapeutics 782 followers 8mo Vasa Therapeutics won the 2025 LONGEVITY BREAKTHROUGH AWARD for a pipeline of novel therapeutics for heart failure and age-related sarcopenia, the two main diseases limiting healthy life span. Thank you to APAC Longevity Society for this prestigious recognition! The awards, presented at the 2025 APAC Longevity Medicine International Summ
Vasa Therapeutics CEO Artur Plonowski to Present VS-214 for PAD at AHA Vascular Discovery 2026 | Vasa Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl
#tunelab #ai #ml #camkii #tunelab #vasatherapeutics #elililly | Vasa Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User … versation is shifting from whether AI will transform drug development to how we apply it rigorously to generate meaningful biological and clinical insight. Looking forward to the discussions ahead. 26 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Adama Ibrahim, EMBA 2mo Report this post AI is transforming drug discovery… or is it? ~90% attrition. Same economics. So what hasn’t changed? On the 29th April, I will be exploring this in a fireside c
Vasa Therapeutics Announces Oral Presentation on VS-214 at the 2026 Vascular Discovery Meeting of American Heart Association | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Vasa Therapeutics to Deliver Two Presentations on VS-041 at ECM2026, Featuring Preclinical and First-in-Human Data and Ongoing Phase 1c Trial Design in HFpEF Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only Ne … arker. Development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01). About Vasa Therapeutics Vasa Therapeutics is a clinical-stage biopharmaceutical company committed to delivering first-inclass innovations for cardiovascular, neuromuscular and age-related disorders. By focusing on mechanisms with strong clinical relevance, Vasa aims to deliver disease-modifying therapie … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
#bio2026 #bioconvention #vasatherapeutics #vs041 #vs214 #hfpef #pad #apelin #endotrophin #camkiidelta #fshd | Vasa Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery … hare to X $6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Vasa Therapeutics, Inc. ("Vasa"), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the closing of series seed funding led by Orphinic Scientific SA ("Orphinic"), an early-stage investor focused on companies with game-changing potential. The round also included participat … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Vasa Therapeutics to Use Eli Lilly AI Platform in Drug Discovery Collaboration | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now … rmaceutical company’s proprietary research data. Under the agreement, Vasa will apply TuneLab’s predictive machine-learning models to support discovery and candidate selection efforts across its pipeline, including its CAMKII delta inhibitor program. The platform is designed to enable external biotechnology companies to access Lilly’s internal drug discovery models while maintaining data privacy through a federated learning framework. Vasa plans to contribute internal experim
Vasa Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 17 Feb 2026 Vasa Therapeutics, Inc. Holding Company | 2019 | California, United States | 10-50 | vasatherapeutics.com Holding Company | 2019 | California, United States | 10-50 | vasatherapeutics.com Last update 17 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Cardiovascular Diseases Nervous System Diseases Other Diseases Synthetic peptide Small molecule drug Disease domain … lar Dystrophy, Facioscapulohumeral Inactive Indication - Drug Highest Phase IND Application First Approval Ctry. / Loc. - First Approval Date - VS-364 Target - Mechanism - Active Org. Vasa Therapeutics, Inc. Originator Org. Vasa Therapeutics, Inc. Active Indication Muscular Atrophy Inactive Indication - Drug Highest Phase Preclinical First Approval Ctry. / Loc. - First Approval Date - 1 Clinical Trials associated with Vasa Therapeutics, Inc. NCT07219511 / Recruiting Phase 1 A … with efficacy. On October 10, 2025, the FDA cleared an Investigational New Drug application for a Phase 1c (Proof-of-Mechanism) study to assess the safety and tolerability of VS-041 in HFpEF participants (NCT07219511). The Phase 1c study is the first clinical trial focused on a subpopulation of the high-risk HFpEF patients identified by an elevated level of serum endotrophin, a biomarker of poor clinical outcomes. The Fast Track designation allows Vasa the opportunity for mor … a the opportunity for more frequent communication with the FDA, eligibility for rolling submission of its future New Drug Application (NDA and the potential for priority review once relevant criteria are met. "The Fast Track Designation for VS-041 treatment of HFpEF marks a significant milestone in our mission to advance a pipeline of drug candidates to address unmet medical needs in large groups of patients, capping off a year of strong execution," added Artur Plonowski, MD, … ease. Development of VS- 041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/10-01). About Heart Failure with Preserved Ejection Fraction (HFpEF) HFpEF is a complex and progressive form of heart failure characterized by stiffening and fibroinflammation of t
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Vasa Therapeutics - Company Profile Solutions Industries Services Resources About Company Directory > Biotech > Vasa Therapeutics ⚠ Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Vasa Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it. REPORT AN ERROR Vasa Therapeutics ↗ Encinitas, USA VISIT WEBSITE Vasa Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular and meta … tors : Orphinic Scientific SA, NuFund Venture Group, SeedFolio, i&i Biotech Fund I PIPELINE Stage : Phase 1 Lead Drug Stage : Phase 1c (Proof-of-Mechanism) Modalities : Small molecule, Peptide analog Active Trials : 1 Trial Phases : Phase 1: 1 FDA Approvals : 0 EMA Approvals : 0 CORPORATE STRUCTURE Subsidiaries : Vasa Therapeutics Sp. z o.o. (Poland) Key Partnerships : Quotient Sciences (Drug development accelerator), Polish National Centre for Research and Development (G
09.03.2024 Vasa Therapeutics Announces Initiation of Phase 1 First-in-Human Clinical Trial of VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, CA, and WROCLAW, POLAND, September 3, 2024 – Vasa Therapeutics (“Vasa”), a clinical stage biopharmaceutical company developing novel therapies for cardiovascular and metabolic aging, announced today that the U.K. Medicines and … ncing was led by Orphinic Scientific SA with participation from i&i Biotech Fund I SCSp. Proceeds will support the clinical development of VS-041 and advancement of Vasa’s preclinical programs. About HFpEF and endotrophin Heart failure is a serious condition that affects more than 64 million people worldwide. 1 Approximately 6.7 million Americans have heart failure, which is expected to increase to over 8.5 million Americans by 2030. 2 Nearly half of patients with hea … inical development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01). About Vasa Therapeutics Vasa is a privately held biopharmaceutical company developing therapeutics that target pathophysiologies of cardiovascular and metabolic aging. In addition to VS-041, Vasa developed a cutting-edge platform for long-acting apelin for combination treatment with incretins in obe
Vasa Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All P … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Vasa Therapeutics Our Mission Our Platform & Pipeline About Us News & Press Publications Contact Right Mechanism. Right Chemistry. Real Patient Impact. Transformative therapies for diseases of cardiovascular, neuromuscular and age-related disorders. Our Mission At Vasa Therapeutics, we design purpose-built therapeutics that precisely target validated disease mechanisms. Our discovery approach aligns the right biology with the right chemistry to create first- and best-in-class therapeutic candidates to treat cardiovascular, neuromuscular and age-related disorders. By focusing on mechani … discovery and clinical translation experience to identify the right mechanism, apply the right chemistry, and translate prior learnings into transformative therapies for cardiovascular, neuromuscular and age-related disorders. Vasa is well-positioned to advance each molecule through a rigorous discovery and validation process designed for precision and improved outcomes. Pipeline Our pipeline reflects a commitment to first-in-class innovation – we apply the right chemistry a … ion from private investments funds NuFund Venture Group, SeedFolio, and others. Grant Projects Preclinical development and phase I clinical trial of innovative drug candidate for heart failure with preserved ejection fraction (HFpEF) (POIR.01.01.01-00-1210/19-01). Value of the project: 13, 220, 234.42 PLN, European Union financing: 10, 186, 082.76 PLN Development of an Innovative MMP Metalloproteinase Inhibitor as a First-in-Class, Disease-Modifying Drug for MMVD and SAS in D